- $384.06m
- $196.79m
- $85.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.91 | ||
| Price to Tang. Book | 0.91 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.5 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24% | ||
| Return on Equity | -13.13% | ||
| Operating Margin | -129.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 130.58 | 97.95 | 106.34 | 91.01 | 85.33 | 81.5 | 83.65 | -9.19% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Directors
- Carlos Paya NEC (62)
- Stephen Linthwaite PRE (49)
- Vikram Jog CFO (64)
- Nicholas Khadder SVP (47)
- Bradley Kreger SVP (46)
- Colin Mccracken OTH (48)
- Nicolas Barthelemy IND (55)
- Gerhard Burbach IND (59)
- Laura Clague IND (62)
- Bill Colston IND (53)
- Ana Stankovic IND (64)
- Last Annual
- December 31st, 2025
- Last Interim
- December 31st, 2025
- Incorporated
- March 29th, 2007
- Public Since
- February 10th, 2011
- No. of Shareholders
- 227
- No. of Employees
- 385
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 390,071,506
- Address
- 50 MILK STREET, 10TH FLOOR, BOSTON, 02109
- Web
- https://www.standardbio.com/
- Phone
- +1 6502666000
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for LAB
Standard BioTools Inc Annual Shareholders Meeting
Q2 2026 Standard BioTools Inc Earnings Release
Similar to LAB
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
Angiodynamics
NASDAQ Global Select Market
FAQ
What is the Standard Biotools share price?
As of Today at 22:25 UTC, shares in Standard Biotools are trading at $0.98. This share price information is delayed by 15 minutes.
How has the Standard Biotools share price performed this year?
Shares in Standard Biotools last closed at $0.98 and the price had moved by -15.12% over the past 365 days. In terms of relative price strength the Standard Biotools share price has underperformed the S&P500 Index by -26.06% over the past year.
What are the analyst and broker recommendations for Standard Biotools?
The overall consensus recommendation for Standard Biotools is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Standard Biotools dividend yield?
Standard Biotools does not currently pay a dividend.
Does Standard Biotools pay a dividend?
Standard Biotools does not currently pay a dividend.
When does Standard Biotools next pay dividends?
Standard Biotools does not currently pay a dividend.
How do I buy Standard Biotools shares?
To buy shares in Standard Biotools you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Standard Biotools?
As of the previous close price of $0.98, shares in Standard Biotools had a market capitalisation of $384.06m.
Where are Standard Biotools shares listed?
Here are the trading details for Standard Biotools:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LAB
What kind of share is Standard Biotools?
Based on an overall assessment of its quality, value and momentum Standard Biotools is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Standard Biotools share price forecast for 2026?
The analyst consensus target price for shares in Standard Biotools is $1.55. That is 57.42% above the last closing price of $0.98.
Analysts covering Standard Biotools currently have a consensus Earnings Per Share (EPS) forecast of -$0.16 for the next financial year.
Find out moreWhat is the trend in the Standard Biotools share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Standard Biotools. Over the past six months, its share price has underperformed the S&P500 Index by -27.65%.
As of the last closing price of $0.98, shares in Standard Biotools were trading -23.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Standard Biotools PE Ratio?
The Standard Biotools PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Standard Biotools?
Standard Biotools' management team is headed by:
- Carlos Paya - NEC
- Stephen Linthwaite - PRE
- Vikram Jog - CFO
- Nicholas Khadder - SVP
- Bradley Kreger - SVP
- Colin Mccracken - OTH
- Nicolas Barthelemy - IND
- Gerhard Burbach - IND
- Laura Clague - IND
- Bill Colston - IND
- Ana Stankovic - IND